![\"\"](\"https:\/\/mira-lab.com\/wp-content\/uploads\/2022\/01\/Untitled-22.jpg\")
<\/p>\n<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
Haemostasis is brought about by the interplay between the blood cells, the blood platelets, vessel endothelium and a set of proteins of the blood plasma, the factors of coagulation system.
\nCoagulation factors are synthesized mainly in liver and circulate in blood plasma in inactive form of proenzymes. During damaging influence
\nproenzymes begin to activate each other in order to form fibrin clot for hemorrhage prevention.
\nThe kit is intended for diagnostics of Hemophilia A and thrombophilia, observation for treatment results and for control testing of anti-hemophilic pharmaceuticals.
\nPrinciple. The base of the method is APTT test in diluted sample. Reduced coagulation factors activity is compensated by adding substrate
\nplasma in incubation medium, which doesn\u2019t contain FVIII but contains full activity of other coagulation factors. So, activity of FVIII in tested
\nsample is the only unknown detecting speed of coagulation process.
\nQuantitative detection of factor VIII is made under calibration graph of dilutions of plasma-calibrator
\nwith certified factor VIII activity.<\/p>\n
FACTOR VIII-TEST<\/strong> <\/p>\n <\/p>\n FACTOR IX-TEST<\/strong> <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n FACTOR VIII<\/strong> <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n FACTOR XIII-TEST<\/strong> <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n PATOPLASMA VIII<\/strong> <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n FACTOR II<\/strong> <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n FACTOR XI<\/strong> <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n FACTOR VII<\/strong> <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n FACTOR XII<\/strong> <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n FACTOR X<\/strong> <\/p>\n <\/p>\n <\/p>\n <\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Haemostasis is brought about by the interplay between the blood cells, the blood platelets, vessel endothelium and a set of proteins of the blood plasma, the factors of coagulation system. Coagulation factors are synthesized mainly in liver and circulate in blood plasma in inactive form of proenzymes. During damaging influence proenzymes begin to activate each other in order to form fibrin clot for hemorrhage prevention. The kit is intended for diagnostics of Hemophilia A and thrombophilia, observation for treatment results and for control testing of anti-hemophilic pharmaceuticals. Principle. The base of the method is APTT test in diluted sample. Reduced coagulation factors activity is compensated by adding substrate plasma in incubation medium, which doesn\u2019t contain FVIII but contains full activity of other coagulation factors. So, activity of FVIII in tested sample is the only unknown detecting speed of coagulation process. Quantitative detection of factor VIII is made under calibration graph of dilutions of plasma-calibrator with certified factor VIII activity. FACTOR VIII-TEST The kit of reagents for FVIII activity determination. Cat. # FC-1 for 20 assays. Reagents: – calibration plasma \u201cRENAM\u201d (1 mL), lyophilized \u2013 1 vial; – substrate plasma (1 mL), activity of factor VIII less than 1%, lyophilized \u2013 1 vial; – erilid (cephalin analog) (1 mL), lyophilized \u2013 1 vial; – kaolin suspension in 0.9 % solution of sodium chloride (5 mL) \u2013 1 vial; – imidazole buffer concentrated (5 mL) \u2013 1 vial; – 0.025 M solution of calcium chloride (5 mL) \u2013 1 vial FACTOR IX-TEST The kit of reagents for F IXb activity determination. Cat. # FC-2-for 20 assays. The kit of reagents is intended for diagnostics of Hemophilia B and thrombophilia, observationfor treatment results and for control testing of antihemophilic pharmaceuticals. FACTOR VIII DEFICIENT PLASMA Cat. # CM-6 (3 vials). FACTOR XIII-TEST The kit of reagents for fibrin-stabilizing factor activity determination. Cat. # FC-3 for 40 assays. Reducing of FXIII level is observed among patients with innate deficit and secondary syndrome at heavy liver injury, sepsis, radiation sickness, after heavy operations. Clinical picture of FXIII deficit is shown by heavy hemorrhagic syndrome, bleeding duration may be 12- 36 hours. PATOPLASMA VIII The control plasma with pathological value of F VIII. Cat. # CM-8\/9 (plasma with F VIII activity~20% – 3 vials, plasma with F VIII activity~200% – 3 vials). FACTOR II DEFICIENT PLASMA Cat. # CM-11 (3 vials). FACTOR XI DEFICIENT PLASMA Cat. # CM-14 (3 vials). FACTOR VII DEFICIENT PLASMA Cat. # CM-12 (3 vials). FACTOR XII DEFICIENT PLASMA Cat. # CM-15 (3 vials). FACTOR X DEFICIENT PLASMA Cat. # CM-13 (3 vials). <\/p>\n","protected":false},"featured_media":4411,"template":"","meta":{"nf_dc_page":""},"product_brand":[],"product_cat":[206],"product_tag":[],"class_list":["post-4410","product","type-product","status-publish","has-post-thumbnail","product_cat-renam","cms-has-post-thumbnail","first","instock","shipping-taxable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/mira-lab.com\/new\/wp-json\/wp\/v2\/product\/4410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mira-lab.com\/new\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/mira-lab.com\/new\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mira-lab.com\/new\/wp-json\/wp\/v2\/media\/4411"}],"wp:attachment":[{"href":"https:\/\/mira-lab.com\/new\/wp-json\/wp\/v2\/media?parent=4410"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/mira-lab.com\/new\/wp-json\/wp\/v2\/product_brand?post=4410"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/mira-lab.com\/new\/wp-json\/wp\/v2\/product_cat?post=4410"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/mira-lab.com\/new\/wp-json\/wp\/v2\/product_tag?post=4410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nThe kit of reagents for FVIII activity determination<\/strong>.
\nCat. # FC-1 for 20 assays.
\nReagents:
\n– calibration plasma \u201cRENAM\u201d (1 mL), lyophilized \u2013 1 vial;
\n– substrate plasma (1 mL), activity of factor VIII less than 1%, lyophilized \u2013 1 vial;
\n– erilid (cephalin analog) (1 mL), lyophilized \u2013 1 vial;
\n– kaolin suspension in 0.9 % solution of sodium chloride (5 mL) \u2013 1 vial;
\n– imidazole buffer concentrated (5 mL) \u2013 1 vial;
\n– 0.025 M solution of calcium chloride (5 mL) \u2013 1 vial<\/p>\n
\nThe kit of reagents for F IXb activity determination. Cat. # FC-2-for 20 assays.
\nThe kit of reagents is intended for diagnostics of Hemophilia B and thrombophilia, observationfor treatment results and
\nfor control testing of antihemophilic pharmaceuticals.<\/p>\n![\"\"](\"https:\/\/mira-lab.com\/wp-content\/uploads\/2022\/01\/Untitled-23.png\")
<\/p>\n
\nDEFICIENT PLASMA Cat. # CM-6 (3 vials).<\/p>\n<\/p>\n
\nThe kit of reagents for fibrin-stabilizing factor activity determination. Cat. # FC-3 for 40 assays.
\nReducing of FXIII level is observed among patients with
\ninnate deficit and secondary syndrome at heavy liver injury, sepsis, radiation
\nsickness, after heavy operations. Clinical picture of FXIII deficit is shown by
\nheavy hemorrhagic syndrome, bleeding duration may be 12- 36 hours.<\/p>\n<\/p>\n
\nThe control plasma with pathological value of F VIII.
\nCat. # CM-8\/9 (plasma with F VIII activity~20% – 3 vials,
\nplasma with F VIII activity~200% – 3 vials).<\/p>\n<\/p>\n
\nDEFICIENT PLASMA Cat. # CM-11 (3 vials).<\/p>\n<\/p>\n
\nDEFICIENT PLASMA Cat. # CM-14 (3 vials).<\/p>\n<\/p>\n
\nDEFICIENT PLASMA Cat. # CM-12 (3 vials).<\/p>\n<\/p>\n
\nDEFICIENT PLASMA Cat. # CM-15 (3 vials).<\/p>\n<\/p>\n
\nDEFICIENT PLASMA Cat. # CM-13 (3 vials).<\/p>\n<\/p>\n